9
Sep
2021
Versant, OrbiMed Invest $50M in Startup Inserting Genes in the Liver
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Sep
2021
Base Editing for Therapeutics: John Evans on The Long Run
John Evans is today’s guest on The Long Run. John is the CEO of Cambridge, Mass.-based Beam Therapeutics. The company was founded a little over three years ago to develop several types of DNA base editing developed in David Liu’s lab at Harvard University, along with an RNA base editor platform developed by Feng Zhang, at the Broad Institute of... Read More
2
Sep
2021
UK ‘Gamechanger’ for Heart Disease, J&J HIV Vaccine Fails, & Purdue Dissolves
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Aug
2021
Meet the Climb to Fight Cancer Postdoctoral Fellow: Aleena Arakaki
I’m excited to announce that the first Climb to Fight Cancer postdoctoral fellow has been selected. This is a position designed to advance the careers of young scientists from traditionally underrepresented minority groups. Aleena Arakaki is the first recipient of this postdoctoral award. She is a Kanaka Maoli (Native Hawaiian) woman. Before describing Arakaki’s background and research, here’s what the... Read More
31
Aug
2021
Atlas, Medicxi Invest $70M in Antibody for Obesity Licensed from Novartis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Aug
2021
Pfizer / BioNTech Vaccine Approved, Lilly Works With Lycia, & We Wait for J&J
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Aug
2021
Computation is the Backstage Enabler in Gene Editing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Aug
2021
Giving Back and Experiencing Nature
Sometimes we need to get away from work, and the news, to recharge our batteries. August is traditionally that time of year for me. I just got back from the summit of Mt. Baker (elevation 10,781 ft) in the North Cascades of Washington. It was another successful mountain trip with terrific biotech people – entrepreneur Julia Owens, investor Dan Bradbury,... Read More
16
Aug
2021
Vaccination and the Delta Variant: Four Steps Forward, Two Steps Back
The news is all about Delta, Delta, Delta, for good reason. The variants are forcing us to ask and answer, again, a whole set of uncomfortable questions. Sobering findings of the past few weeks have shaken both the American and scientific psyche. People have had to re-assess their perceptions about the COVID-19 vaccines, and the re-emergence of an epidemic many... Read More
12
Aug
2021
Is EQRx an Existential Threat to the Biopharma Industry?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Aug
2021
Better Cancer Drugs for Kids: Julie Grant and Sam Blackman on The Long Run
Today we have a pair of guests on The Long Run — Julie Grant and Sam Blackman. Julie is a venture capitalist – a general partner at Canaan Partners. Sam is a pediatric oncologist and drug developer. After a routine business meeting, they realized they had something in common. They both believed that the pharmaceutical industry can — and should... Read More
5
Aug
2021
Bayer Snaps Up Vividion, Sanofi Grabs Translate Bio, and RIP: Tachi Yamada
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2021
Tachi Yamada, Physician-Scientist-Biopharma Industry Leader, Dies at 76
Tadataka “Tachi” Yamada, a distinguished physician-scientist who became a biopharmaceutical industry leader and a deeply respected advisor to biotech entrepreneurs, died the morning of Aug. 4. He was 76. Yamada died from a heart attack while exercising at home in Seattle, said his son, Takao. “He was a special person who did things to help people. That was his North... Read More
4
Aug
2021
Sonoma Bio, Engineering T-cell Therapies for Autoimmunity, Nabs $265M Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Aug
2021
All Inclusive Medicine Needs More Diverse Genomic Data
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Aug
2021
Kidney Companies Taking Pages from Precision Oncology Playbook
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jul
2021
FDA Rejections, Midsummer IPOs & Amgen’s Bispecific Buy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jul
2021
An Industry that Depends on Diversity Should Defend It
[Editor’s Note: I asked Paul to write in response to a biotech executive who’s marketing a new book that claims diversity and inclusion in business is “the defining scam of our time.”] As CEO of a cell therapy company, I know that the human immune system is a pointillist masterpiece, containing trillions of B and T cells with unique antigen... Read More
26
Jul
2021
Career Arc of a Biotech Leader: Sue Desmond-Hellmann on The Long Run
Today’s guest on The Long Run is Sue Desmond-Hellmann. Sue — and I don’t say this about many people — is a biotech industry legend. Sue is an oncologist and a public health professional by training. She made her name in biopharmaceuticals at Genentech from 1995-2009 — the glory days when it became the world’s most important developer of new... Read More
22
Jul
2021
Biogen’s Bumbling Defense, Delta on the Move, & PacBio’s Power Play
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.